LUNG Stock Overview
A commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Pulmonx Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.00 |
| 52 Week High | US$14.84 |
| 52 Week Low | US$7.11 |
| Beta | 0.66 |
| 1 Month Change | 19.84% |
| 3 Month Change | -37.54% |
| 1 Year Change | -28.63% |
| 3 Year Change | -78.13% |
| 5 Year Change | n/a |
| Change since IPO | -77.11% |
Recent News & Updates
Recent updates
Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion
Apr 04
Pulmonx: Revisiting Thesis Following Management Change
Mar 26Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?
Feb 23Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues
Aug 01Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically
Nov 08Pulmonx GAAP EPS of -$0.40 in-line, revenue of $14M beats by $0.23M
Aug 02Pulmonx: Interesting Technology But Struggling With Adoption
Jul 02These Analysts Just Made A Meaningful Downgrade To Their Pulmonx Corporation (NASDAQ:LUNG) EPS Forecasts
Feb 28Shareholder Returns
| LUNG | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.6% | 2.3% | 1.8% |
| 1Y | -28.6% | 1.5% | 26.1% |
Return vs Industry: LUNG underperformed the US Medical Equipment industry which returned 1.5% over the past year.
Return vs Market: LUNG underperformed the US Market which returned 26.1% over the past year.
Price Volatility
| LUNG volatility | |
|---|---|
| LUNG Average Weekly Movement | 10.9% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: LUNG's share price has been volatile over the past 3 months.
Volatility Over Time: LUNG's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 279 | Steve Williamson | pulmonx.com |
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves.
Pulmonx Corporation Fundamentals Summary
| LUNG fundamental statistics | |
|---|---|
| Market cap | US$349.34m |
| Earnings (TTM) | -US$58.73m |
| Revenue (TTM) | US$72.99m |
4.8x
P/S Ratio-5.9x
P/E RatioIs LUNG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LUNG income statement (TTM) | |
|---|---|
| Revenue | US$72.99m |
| Cost of Revenue | US$18.75m |
| Gross Profit | US$54.24m |
| Other Expenses | US$112.97m |
| Earnings | -US$58.73m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 74.31% |
| Net Profit Margin | -80.46% |
| Debt/Equity Ratio | 33.7% |
How did LUNG perform over the long term?
See historical performance and comparison